AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15482080
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment plus abstinent-contingent housing and work (DT+)
Trial: 15482080
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment only (DT)
Trial: 9625308
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg three times daily)
Trial: 7574219
Drug: Aspirin, 325
RxNorm normalized name: Aspirin, 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 325 mg/d
Trial: 2168814
Drug: Qigong and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qigong and antihypertensive drugs at low dosage
Trial: 2168814
Drug: WM group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WM group (antihypertensive drugs alone)
Trial: 30156030
Drug: Low CoQ10
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low CoQ10 levels (<0.5 μg/mL) in patients with acute influenza
Trial: 28359749
Drug: Multidomain intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidomain intervention plus omega 3 polyunsaturated fatty acids (800 mg DHA and 225 mg EPA daily)
Trial: 23565930
Drug: Prilocaine irrigation
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prilocaine irrigation (30 mL of 2% prilocaine)
Trial: 23565930
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prilocaine-free irrigation solution)
Trial: 10911005
Drug: Continued medical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medical treatment
Trial: 7931883
Drug: Combination phototherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination phototherapy
Trial: 30130712
Drug: Sarcosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (2 g)
Trial: 18984493
Drug: Group-based program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based program for obese children and adolescents consisting of modules for physical activity, nutritional education, and coping strategies performed twice each week for 1 year with parental participation and medical supervision.
Trial: 12582838
Drug: GABA(A) agonist
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA(A) agonist lorazepam
Trial: 9206051
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen therapy (20mg daily for 2 to 5 years)
Trial: 9206051
Drug: No tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No tamoxifen therapy (control group)
Trial: 2835055
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) 2,500 U s.c. once daily
Trial: 2835055
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) 5,000 U s.c. twice daily with dihydroergotamine (DHE) 0.5 mg s.c.
Trial: 30064032
Drug: Palm oil
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palm oil plus Sn solution
Trial: 30064032
Drug: Sn solution
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sn solution (positive control)
Trial: 28283026
Drug: Depot medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot medroxyprogesterone acetate injection (DMPA)
Trial: 28283026
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pill (COCP)
Trial: 23735957
Drug: Intraventricular application
RxNorm normalized name: cerliponase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraventricular application of recombinant tissue‐type plasminogen activator and lateral rotational therapy (experimental)
Trial: 20464617
Drug: GONB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + triamcinolone 40 mg (group B)
Trial: 14609894
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1 g of EMLA 60 to 90 minutes before lumbar puncture
Trial: 8677067
Drug: Dexamethasone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (5 mg every 12 hours for a total of four doses)
Trial: 1464896
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg single dose)
Trial: 1464896
Drug: Captopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (2 x 25 mg for two weeks)
Trial: 24270933
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine 0.1 mg/kg with promethazine 25 mg
Trial: 24270933
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine 0.1 mg/kg
Trial: 22506833
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection with the X‐Tip system
Trial: 22506833
Drug: Periodontal ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal ligament injections (PDL)
Trial: 16285944
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human PYY3-36 (highest dose)
Trial: 2143063
Drug: Intravenous fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fluorouracil
Trial: 422100
Drug: Benzbromarone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzbromarone (50 mg to 100 mg/day)
Trial: 21874538
Drug: Pitavastatin 4
RxNorm normalized name: PITAVASTATIN 4MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg once daily for 12 weeks
Trial: 21874538
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg once daily for 12 weeks
Trial: 2888253
Drug: Morphine-Scopolamine (Mo-Scop)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-Scopolamine (Mo-Scop)
Trial: 27667332
Drug: Intradermal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal delivery of virosomal vaccine using MicronJet600™
Trial: 27667332
Drug: 45μg dose
RxNorm normalized name: tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45μg dose of virosomal vaccine formulation
Trial: 25266414
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow rate of 2 l/min (group D2)
Trial: 25266414
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow rate of 4 l/min (group D4)
Trial: 25266414
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow rate of 6 l/min (group D6)
Trial: 22644708
Drug: Insulin-loaded HA
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-loaded HA nanoparticles
Trial: 22644708
Drug: Insulin solution
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin solution
Trial: 20356587
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral contraceptives (OC) and prednisolone (OC/Pr)
Trial: 18177922
Drug: High-dose lumiracoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lumiracoxib
Trial: 10925684
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (CMF: cyclophosphamide 100 mg/body on days 1‐14; methotrexate 40 mg/m2 on days 1 and 8; 5‐fluorouracil 500 mg/m2 on days 1 and 8)
Trial: 10925684
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (UFT 300 mg/day and tamoxifen 30 mg/day for 2 years)
Trial: 8844884
Drug: Radiotherapy doses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy doses ranging from 0.4 to 5.2 Gy per fraction
Trial: 8844884
Drug: Radiotherapy doses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy doses less than 1.5 Gy per fraction
Trial: 8844884
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment fractions (5, 10, 12, and 20 daily treatment fractions)
Trial: 4029019
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (0.5g and 1g)
Trial: 16210963
Drug: Alemtuzumab with
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab with low-dose cyclosporine (CsA)
Trial: 16210963
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (full doses of CsA with azathioprine and corticosteroids)
Trial: 12078913
Drug: Escalated BEACOPP
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated BEACOPP (four escalated cycles followed by four at baseline dose)
Trial: 7545380
Drug: DDAVP infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP infusion (group I)
Trial: 7545380
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (group II)
Trial: 30353743
Drug: Lixisenatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (20 μg, 8 weeks)
Trial: 30353743
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (titrated once-daily)
Trial: 23795871
Drug: Substance use
RxNorm normalized name: reSET Substance Use Disorder Therapy Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance use treatment (Brief Strategic Family Therapy)
Trial: 18819961
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (>/=200 mg)
Trial: 18819961
Drug: Moderate-dose aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose aspirin (101-199 mg)
Trial: 18819961
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (</=100 mg)
Trial: 18819961
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (>/=200 mg) vs Low-dose aspirin (</=100 mg)
Trial: 7977774
Drug: 10% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% amino acid solution infused at 0.5 ml.kg‐1.min‐1 (group I)
Trial: 7977774
Drug: 10% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% amino acid solution infused at 1.0 ml.kg‐1.min‐1 (group II)
Trial: 7977774
Drug: 10% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% amino acid solution infused at 2.0 ml.kg‐1.min‐1 (group III)
Trial: 7977774
Drug: 10% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% amino acid solution infused at 4.0 ml.kg‐1.min‐1 (group IV)
Trial: 7977774
Drug: 10% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% amino acid solution infused at 6.0 ml.kg‐1.min‐1 (group V)
Trial: 31868684
Drug: Levodopa (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (regular dose)
Trial: 26750388
Drug: 12-week Cognitive
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week Cognitive Behavioural Therapy-based group treatment for hoarding disorder
Trial: 21789385
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 1.5 ng/mL (group I)
Trial: 21789385
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 2 ng/mL (group II)
Trial: 21789385
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 2.5 ng/mL (group III)
Trial: 16954359
Drug: Low-polyphenol olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-polyphenol olive oil (2.7 mg/kg)
Trial: 16954359
Drug: Medium-polyphenol olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-polyphenol olive oil (164 mg/kg)
Trial: 16954359
Drug: High-polyphenol olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-polyphenol olive oil (366 mg/kg)
Trial: 11361046
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) oxycodone q12h
Trial: 11361046
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) oxycodone qid
Trial: 29931358
Drug: 60 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 μg (2400 IU)/d of D3
Trial: 29931358
Drug: 20 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg/d of 25(OH)D3
Trial: 23154532
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline based on insulin intensive therapy
Trial: 10223232
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with alpha-fetoprotein level <10 ng/mL
Trial: 28698075
Drug: Metformin (1500mg/day)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (1500mg/day) with Clomiphene citrate (100mg/day)
Trial: 20727236
Drug: Juice Plus+®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juice Plus+® (dietary supplement from fruits and vegetables)
Trial: 19165198
Drug: Standard AC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard AC (doxorubicin 60 mg m(‐2) + cyclophosphamide 600 mg m(‐2) every 3 weeks)
Trial: 19165198
Drug: Accelerated AC
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated AC (doxorubicin 60 mg m(‐2) + cyclophosphamide 600 mg m(‐2) every 2 weeks with pegfilgrastim)
Trial: 19165198
Drug: Combined EC
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined EC (epirubicin 90 mg m(‐2) every 3 weeks or every 2 weeks with pegfilgrastim)
Trial: 14505238
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of parenteral Cefazolin preoperatively
Trial: 9022487
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin and heparin (5000 U of unfractionated heparin subcutaneously 12 hourly)
Trial: 29926217
Drug: Test lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Test lenalidomide capsule (25 mg)
Trial: 29926217
Drug: Revlimid® capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revlimid® capsule (25 mg)
Trial: 19842347
Drug: Notched noise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Notched noise stimuli (windowed sound therapy [WST])
Trial: 15468963
Drug: CsA alone
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA alone (2-3 mg/kg/d)
Trial: 15468963
Drug: CsA after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA after intravenous pulse methylprednisolone therapy (CsA/PMT) (2-3 mg/kg/d)
Trial: 15468963
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (PSL, 40-60 mg/d)
Trial: 9309990
Drug: Mannitol inhalation
RxNorm normalized name: mannitol inhalation kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol inhalation (5, 10, 20, or 40 mg to a cumulative dose of 635 mg)
Trial: 9309990
Drug: Mannitol inhalation
RxNorm normalized name: mannitol inhalation kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol inhalation (first challenge)
Trial: 9309990
Drug: Mannitol inhalation
RxNorm normalized name: mannitol inhalation kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol inhalation (second challenge)
Trial: 30786829
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 (10 mg/day)
Trial: 27282852
Drug: Gambrosol Trio
RxNorm normalized name: Simparica TRIO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gambrosol Trio (biocompatible PD solution)
Trial: 27282852
Drug: Standard PD
RxNorm normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PD solution (Dianeal)
Trial: 27282852
Drug: Gambrosol Trio
RxNorm normalized name: Simparica TRIO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gambrosol Trio and Standard PD solution
Trial: 20417925
Drug: Subconjunctival ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered 3 days prior to surgery (Group 1, n = 5)
Trial: 20417925
Drug: Subconjunctival ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered at the time of surgery (Group 2, n = 5)
Trial: 16003294
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d of simvastatin
Trial: 16003294
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d of atorvastatin
Trial: 7549167
Drug: 0.0625% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% bupivacaine with 2 micrograms/ml fentanyl via PCEA
Trial: 7549167
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine with 2 micrograms/ml fentanyl via continuous epidural infusion (CEI)
Trial: 1940776
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (3 g daily)
Trial: 1940776
Drug: Acipimox (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (0.75 g daily)
Trial: 6779890
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol (4 mg)
Trial: 6779890
Drug: Tablet (4
RxNorm normalized name: KISQALI Tablet (400mg daily dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (4 mg)
Trial: 31395485
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (TA) at a dose of 2 mg kg‐1 IV and then IM
Trial: 31395485
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (TA) at a dose of 4 mg kg‐1 IV
Trial: 28618772
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of pitavastatin
Trial: 28618772
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of pitavastatin
Trial: 22975753
Drug: tissue inhibitor
RxNorm normalized name: Tissue inhibitor of metalloproteinases 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tissue inhibitor of metalloproteinases-1 (TIMP-1)
Trial: 17462615
Drug: roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (150 mg) and ambroxol HCl (30 mg) dispersible tablet (treatment A)
Trial: 17462615
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg roxithromycin dispersible tablet and 30 mg ambroxol HCl tablet (treatment B)
Trial: 17462615
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg roxithromycin dispersible tablet (treatment C)
Trial: 17462615
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ambroxol HCl tablet (treatment D)
Trial: 11296098
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion (150 microg)
Trial: 11296098
Drug: CCK‐4 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐4 administration
Trial: 9247907
Drug: Metformin (Glucophage)
RxNorm normalized name: metformin Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (Glucophage) with standard diet and exercise